Intech Investment Management LLC Purchases 24,009 Shares of Haemonetics Co. (NYSE:HAE)

Intech Investment Management LLC raised its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 107.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,338 shares of the medical instruments supplier's stock after purchasing an additional 24,009 shares during the period. Intech Investment Management LLC owned 0.09% of Haemonetics worth $3,618,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Arizona State Retirement System increased its position in Haemonetics by 1.2% during the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier's stock valued at $1,160,000 after purchasing an additional 181 shares during the period. Parkside Financial Bank & Trust raised its stake in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the last quarter. HighTower Advisors LLC lifted its holdings in Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after buying an additional 244 shares during the period. Segall Bryant & Hamill LLC grew its holdings in Haemonetics by 0.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier's stock worth $5,033,000 after acquiring an additional 407 shares during the period. Finally, Isthmus Partners LLC raised its position in shares of Haemonetics by 1.1% in the 4th quarter. Isthmus Partners LLC now owns 40,220 shares of the medical instruments supplier's stock worth $3,140,000 after acquiring an additional 450 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HAE shares. JPMorgan Chase & Co. began coverage on Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock. Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research lowered their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, JMP Securities dropped their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $101.22.

Haemonetics Stock Performance

HAE stock traded up $0.55 during mid-day trading on Monday, hitting $64.55. The company had a trading volume of 365,867 shares, compared to its average volume of 649,946. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97. The stock's fifty day moving average price is $67.29 and its two-hundred day moving average price is $75.03. The firm has a market cap of $3.24 billion, a PE ratio of 25.41, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.